Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00478387 · ClinicalTrials.gov registry record
Ovarian Cancer and Immune Response to Flu Vaccine
A clinical trial, sponsored by University of Pennsylvania.
- Completed
- Registry status
- 37
- Enrollment target
NCT00478387: Completed study, sponsored by University of Pennsylvania.
NCT00478387 is a clinical trial that has completed, run by University of Pennsylvania. The registered enrollment target is 37 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00478387 has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- 37 participants
- Enrollment target
Study Summary
The purpose of this study is to determine what the immune response is of ovarian cancer patients in remission, when they are given the flu vaccine. After receiving the flu vaccine, patients will have blood drawn 5 times in 12 months to study antibody response to the flu vaccine.
Interventions
- BIOLOGICAL The current season's trivalent killed influenza vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2006-10 |
| Est. Completion | 2011-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00478387
The ClinicalTrials.gov registry entry for NCT00478387 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which The current season's trivalent killed influenza vaccine is the first listed.
NCT00478387 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00478387 about?
NCT00478387 is a clinical study titled "Ovarian Cancer and Immune Response to Flu Vaccine". The purpose of this study is to determine what the immune response is of ovarian cancer patients in remission, when they are given the flu vaccine. After receiving the flu vaccine, patients will have blood drawn 5 times in 12 months to study antibody response to the flu vaccine.
What is the current status of trial NCT00478387?
This trial is currently completed. The enrollment target is 37 participants. The study started on 2006-10. Estimated completion is 2011-06.
What interventions are being tested in trial NCT00478387?
The interventions under investigation include: The current season's trivalent killed influenza vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00478387?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.